A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

  • Cancer
  • Lung Cancer
  • Small Cell Lung Carcinoma
  • Small Cell Lung Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Athens
  • Bahia
  • bei-jing-shi
  • Beograd
  • Binghamton
  • Bordeaux
  • Budapest
  • Bunkyo City
  • Caen
  • California
  • Camperdown
  • Charlotte
  • Chattanooga
  • Chermside
  • Chicago
  • Ciudad de México
  • Debrecen
  • Exeter
  • Fairfax
  • Fort Myers
  • Fukuoka
  • Gauting
  • Gdańsk
  • Großhansdorf
  • guang-zhou-shi
  • Halle (Saale)
  • hang-zhou-shi
  • Harbin
  • Heidelberg
  • Himeji
  • Hlavní město Praha
  • Immenhausen
  • Ina
  • jilin-city
  • Kifisia
  • Koto City
  • Kurashiki
  • Kyoto
  • Las Vegas
  • Lazio
  • Lille
  • Linz
  • Lombardia
  • London
  • Louisville
  • Madison
  • Madrid
  • Manchester
  • Marietta
  • Marseille
  • Milano
  • Moscow Oblast
  • Moskva
  • Málaga
  • Nagaizumi
  • Nanjing
  • Nashville
  • Niš
  • Novosibirsk
  • olomouc-9
  • Olsztyn
  • Orlando
  • Osakasayama
  • Otwock
  • Paramus
  • Parkville
  • Parma
  • Peoria
  • Pisa
  • Porto Alegre
  • Poznań
  • Providencia
  • Recoleta
  • Rio
  • Rio Grande do Sul
  • Roanoke
  • Rochester
  • Saint Petersburg
  • Sakai
  • Salzburg
  • San Giovanni Rotondo
  • Sankt-Peterburg
  • sant-andreu-de-la-barca
  • Scarborough
  • Sendai
  • Seongnam-si
  • Seoul
  • Sevilla
  • shang-hai-shi
  • Shanghai
  • St. Petersburg
  • São Paulo
  • Tacoma
  • Taipei City
  • Taoyuan City
  • Törökbálint
  • Wakayama
  • Wien
  • Yokohama
  • Zaragoza
  • zheng-zhou-shi
  • Zion
  • Łódź
Trial Identifier:

NCT02763579 2015-004861-97 GO30081

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02763579,GO30081,2015-004861-97 Trial Identifier
      Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide, Placebo Treatments
      Small Cell Lung Carcinoma Condition
      Official Title

      A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)
      • No prior systemic treatment for ES-SCLC
      • Eastern Cooperative Oncology Group performance status of 0 or 1
      • Measurable disease, as defined by RECIST v1.1
      • Adequate hematologic and end organ function
      • Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
      Exclusion Criteria
      • Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation
      • Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
      • Pregnant or lactating women
      • History of autoimmune disease
      • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
      • Positive test result for human immunodeficiency virus (HIV)
      • Active hepatitis B or hepatitis C
      • Severe infections at the time of randomization
      • Significant cardiovascular disease
      • Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti-PD-L1 therapeutic antibody
      • History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now